– Bloomberg
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Revolution Medicines Inc (NASDAQ:RVMD) announced that Sanofi SA (NASDAQ:SNY) has terminated global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will…